MX367358B - Composiciones farmaceuticas que comprenden azd9291. - Google Patents

Composiciones farmaceuticas que comprenden azd9291.

Info

Publication number
MX367358B
MX367358B MX2016008744A MX2016008744A MX367358B MX 367358 B MX367358 B MX 367358B MX 2016008744 A MX2016008744 A MX 2016008744A MX 2016008744 A MX2016008744 A MX 2016008744A MX 367358 B MX367358 B MX 367358B
Authority
MX
Mexico
Prior art keywords
azd9291
pharmaceutical compositions
pharmaceutical
compositions
enamide
Prior art date
Application number
MX2016008744A
Other languages
English (en)
Other versions
MX2016008744A (es
Inventor
Wilson David
Finnie Cindy
Anthony Raw Steven
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50191689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367358(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2016008744A publication Critical patent/MX2016008744A/es
Publication of MX367358B publication Critical patent/MX367358B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con composiciones farmacéuticas adecuadas para la administración oral, y más particularmente con composiciones farmacéuticas, incluyendo composiciones de tabletas farmacéuticas, que contienen N-(2-{2-dimetilaminoetil-metilamino}-4-metoxi-5-{[4-(1-metilindol -3-il)pirimidin-2-il]amino}fenil)prop-2-enamida ("AZD9291 ") o una sal farmacéuticamente aceptable del mismo, en donde tales composiciones comprenden una cierta cantidad de celulosa microcristalina y al menos otro diluyente farmacéutico.
MX2016008744A 2014-01-02 2015-01-02 Composiciones farmaceuticas que comprenden azd9291. MX367358B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1400034.3A GB201400034D0 (en) 2014-01-02 2014-01-02 Pharmaceutical Compositions comprising AZD9291
PCT/GB2015/050001 WO2015101791A1 (en) 2014-01-02 2015-01-02 Pharmaceutical compositions comprising azd9291

Publications (2)

Publication Number Publication Date
MX2016008744A MX2016008744A (es) 2016-09-08
MX367358B true MX367358B (es) 2019-08-16

Family

ID=50191689

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008744A MX367358B (es) 2014-01-02 2015-01-02 Composiciones farmaceuticas que comprenden azd9291.

Country Status (37)

Country Link
US (6) US10183020B2 (es)
EP (1) EP3089741B1 (es)
JP (1) JP6588915B2 (es)
KR (1) KR102336378B1 (es)
CN (2) CN114712362A (es)
AR (1) AR098989A1 (es)
AU (1) AU2015204218B2 (es)
CA (1) CA2933403C (es)
CL (1) CL2016001609A1 (es)
CR (1) CR20160310A (es)
CY (1) CY1124848T1 (es)
DK (1) DK3089741T3 (es)
DO (1) DOP2016000156A (es)
EA (1) EA034243B9 (es)
ES (1) ES2873226T3 (es)
GB (1) GB201400034D0 (es)
GT (1) GT201600142A (es)
HR (1) HRP20210749T1 (es)
HU (1) HUE054344T2 (es)
IL (1) IL246186B (es)
LT (1) LT3089741T (es)
MX (1) MX367358B (es)
MY (1) MY183536A (es)
NI (1) NI201600098A (es)
NZ (1) NZ721298A (es)
PE (1) PE20161170A1 (es)
PH (1) PH12016501310B1 (es)
PL (1) PL3089741T3 (es)
PT (1) PT3089741T (es)
RS (1) RS61927B1 (es)
SG (1) SG11201605339QA (es)
SI (1) SI3089741T1 (es)
SM (1) SMT202100330T1 (es)
TW (1) TWI702953B (es)
UY (1) UY35933A (es)
WO (1) WO2015101791A1 (es)
ZA (1) ZA201605300B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (es) 2014-01-24 2018-02-24
CN109311858B (zh) 2016-05-26 2021-12-03 里科瑞尔姆Ip控股有限责任公司 Egfr抑制剂化合物
CN108057036B (zh) * 2016-11-07 2023-06-13 正大天晴药业集团股份有限公司 一种egfr抑制剂的固体药物组合物
CN107176954B (zh) * 2017-06-02 2019-01-11 无锡双良生物科技有限公司 一种egfr抑制剂的药用盐及其晶型、制备方法和应用
CN110013468B (zh) * 2018-01-09 2022-02-18 北京福元医药股份有限公司 一种azd9291氘代衍生物药物制剂
WO2019138346A1 (en) * 2018-01-10 2019-07-18 Alembic Pharmaceuticals Limited Pharmaceutical composition of osimertinib
MX2020008395A (es) 2018-02-12 2020-09-21 Astrazeneca Ab Osimertinib para su uso en el tratamiento de cáncer de pulmón de células no pequeñas.
FI3758708T3 (fi) * 2018-03-01 2025-02-18 Astrazeneca Ab (2s)-{(1s)-1-syano-2-[4-(3-metyyli-2-okso-2,3-dihydro-1,3-bentsoksatsol-5-yyli)fenyyli]etyyli}-1,4-oksatsepaani-2-karboksamidia käsittäviä farmaseuttisia koostumuksia
WO2019178868A1 (zh) 2018-03-23 2019-09-26 无锡双良生物科技有限公司 一种药物组合物及其制备方法和用途
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
AU2020250832A1 (en) 2019-03-29 2021-11-11 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
JP2023510426A (ja) 2020-01-20 2023-03-13 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
TW202304457A (zh) * 2021-03-22 2023-02-01 瑞典商阿斯特捷利康公司 配製物
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
CA3249080A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN CANCER TREATMENT
IL317733A (en) 2022-06-27 2025-02-01 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for cancer treatment
CA3261476A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Combination with HGF Receptor Inhibitors for the Treatment of Cancer
IL321931A (en) 2023-01-06 2025-09-01 Insmed Inc New and reversible DPP1 inhibitors and their uses
WO2025092926A1 (zh) * 2023-10-31 2025-05-08 浙江同源康医药股份有限公司 一种嘧啶类衍生物的药物组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110376A (en) * 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
WO2001076565A1 (fr) * 2000-04-12 2001-10-18 Banyu Pharmaceutical Co., Ltd. Compositions et preparations se desintegrant dans la cavite buccale
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
ES2286406T3 (es) 2002-02-26 2007-12-01 Astrazeneca Ab Formulacion farmaceutica de iressa que comprende un derivado de celulosa soluble en agua.
US20080102133A1 (en) * 2004-10-05 2008-05-01 Antje Brueck-Scheffler Oral Pharmaceutical Preparation for Proton Pump Antagonists
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
CA2642665C (en) * 2006-02-09 2013-01-08 Daiichi Sankyo Company, Limited Anti-cancer pharmaceutical composition
JP5576922B2 (ja) * 2006-04-20 2014-08-20 信越化学工業株式会社 腸溶性固体分散体を含んでなる固形製剤
CA2692977A1 (en) * 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
EP2696857A1 (en) 2011-04-11 2014-02-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising bosentan
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
ME02887B (me) * 2011-07-27 2018-04-20 Astrazeneca Ab 2-(2,4,5-supstituisani-anilino) pirimidinski derivati kao egfr modulatori korisni za tretman raka
WO2013105895A1 (en) * 2012-01-13 2013-07-18 Xspray Microparticles Ab A pharmaceutical composition comprising stable, amorphous hybrid nanopraticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component
WO2013160916A1 (en) 2012-04-25 2013-10-31 Hetero Research Foundation Sunitinib malate solid dispersion
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291

Also Published As

Publication number Publication date
KR20160101720A (ko) 2016-08-25
ZA201605300B (en) 2022-10-26
PL3089741T3 (pl) 2021-09-27
AR098989A1 (es) 2016-06-22
GB201400034D0 (en) 2014-02-19
CA2933403C (en) 2022-03-29
US20250017930A1 (en) 2025-01-16
JP2017501201A (ja) 2017-01-12
HUE054344T2 (hu) 2021-08-30
AU2015204218A1 (en) 2016-07-07
EA034243B1 (ru) 2020-01-21
UY35933A (es) 2015-07-31
DK3089741T3 (da) 2021-06-07
KR102336378B1 (ko) 2021-12-08
IL246186B (en) 2020-07-30
CA2933403A1 (en) 2015-07-09
LT3089741T (lt) 2021-06-10
US20200360378A1 (en) 2020-11-19
GT201600142A (es) 2019-08-12
TWI702953B (zh) 2020-09-01
WO2015101791A1 (en) 2015-07-09
DOP2016000156A (es) 2016-08-15
PH12016501310B1 (en) 2022-07-06
US10183020B2 (en) 2019-01-22
EA201691242A1 (ru) 2016-12-30
US20190111057A1 (en) 2019-04-18
ES2873226T3 (es) 2021-11-03
JP6588915B2 (ja) 2019-10-09
RS61927B1 (sr) 2021-06-30
IL246186A0 (en) 2016-07-31
PE20161170A1 (es) 2016-11-24
SG11201605339QA (en) 2016-07-28
CN114712362A (zh) 2022-07-08
EP3089741A1 (en) 2016-11-09
EP3089741B1 (en) 2021-03-10
CN105848647A (zh) 2016-08-10
NZ721298A (en) 2017-10-27
US20240189310A1 (en) 2024-06-13
MY183536A (en) 2021-02-25
MX2016008744A (es) 2016-09-08
NI201600098A (es) 2016-12-20
PH12016501310A1 (en) 2016-09-14
CN105848647B (zh) 2022-04-26
HRP20210749T1 (hr) 2021-06-25
CR20160310A (es) 2016-09-23
CY1124848T1 (el) 2022-11-25
US20220395502A1 (en) 2022-12-15
CL2016001609A1 (es) 2016-12-09
TW201609101A (zh) 2016-03-16
HK1225655A1 (zh) 2017-09-15
EA034243B9 (ru) 2020-04-10
SMT202100330T1 (it) 2021-07-12
AU2015204218B2 (en) 2017-06-15
US20160324854A1 (en) 2016-11-10
PT3089741T (pt) 2021-06-11
SI3089741T1 (sl) 2021-08-31

Similar Documents

Publication Publication Date Title
MY183536A (en) Pharmaceutical compositions comprising azd9291
JOP20200122A1 (ar) مركبات مفيدة لتثبيط cdk7
MX369818B (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
PH12013502277A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4 methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
MX394588B (es) Composición farmacéutica.
TN2016000489A1 (en) Carboxamide derivatives.
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
TN2016000491A1 (en) Carboxamide derivatives.
PH12017501444A1 (en) (2r,4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
AU2015280874A1 (en) Novel heterocyclic compound
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
PH12019500567A1 (en) Crystalline forms
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
PH12017501832A1 (en) Stabilized pharmaceutical composition
PH12016502527B1 (en) Stabilized desmopressin
PH12018500946A1 (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
TR201721065A2 (tr) Deksmedetomi̇di̇n i̇çeren li̇yofi̇li̇ze farmasöti̇k formülasyonlar
TN2013000440A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
GR1008804B (el) Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα

Legal Events

Date Code Title Description
FG Grant or registration